Biora Therapeutics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2010-01-01
- Employees
- 58
- Market Cap
- $25M
- Introduction
Biora Therapeutics, Inc. engages in the provision of molecular and specialized diagnostic tests to clinicians. Its products include the Preparent Carrier Test, Innatal Prenatal Screen, Riscover Hereditary Cancer Test, and Resura Prenatal Test. The company was founded by Paul W. Hawran and Harry Stylli in 2010 and is headquartered in San Diego, CA.
Biora Therapeutics Undertakes Chapter 11 Sale Process to Position Business for Future Growth
Biora Therapeutics secures up to $10.25M in financing for a chapter 11 sale process, aiming to strengthen its balance sheet and support product development, including the BioJet and NaviCap platforms.
Novel Drug Maintained Clinical Improvements in IBD
Tulisokibart maintained clinical and endoscopic improvements in IBD patients through week 50 in phase II trial extensions, with 48% of ulcerative colitis patients and 56% of Crohn's disease patients achieving clinical remission. The drug was well-tolerated with no identified safety signals.
Tulisokibart bests placebo, may yield 'important clinical benefit' via TL1A blockade in UC
Tulisokibart, an anti-TL1A monoclonal antibody, outperformed placebo in inducing clinical remission at week 12 in moderate to severe ulcerative colitis, according to the ARTEMIS-UC trial. The study incorporated a predictive biomarker for response, showing significant clinical remission, endoscopic improvement, and clinical response in patients on tulisokibart compared to placebo. A phase 3 program is planned to confirm these results.
© Copyright 2025. All Rights Reserved by MedPath